Detalhe da pesquisa
1.
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Br J Haematol
; 204(1): 191-205, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38011941
2.
Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Haematologica
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38721745
3.
A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers.
Haematologica
; 2024 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38899342
4.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1131-1143, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162177
5.
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
Haematologica
; 107(11): 2685-2697, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35484662
6.
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Haematologica
; 105(11): 2584-2591, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33131247
7.
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Mar Drugs
; 18(12)2020 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33291602
8.
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Br J Haematol
; 187(5): 595-601, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355927
9.
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Haematologica
; 104(8): 1633-1639, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733273
10.
In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103.
Br J Haematol
; 200(5): 669-672, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484636
11.
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Br J Haematol
; 178(6): 936-948, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653353
12.
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
Br J Haematol
; 184(6): 1022-1025, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29611184
13.
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
Haematologica
; 104(7): e307-e309, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679329
14.
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
Mol Cancer Ther
; 23(4): 520-531, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324336
15.
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Mol Cancer Ther
; 23(3): 368-380, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052765
16.
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
J Clin Med
; 12(2)2023 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36675328
17.
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Am J Cancer Res
; 13(5): 2076-2086, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37293172
18.
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo.
Eur J Med Chem
; 246: 114997, 2023 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36502578
19.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Cancer Res Commun
; 3(4): 576-591, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37066023
20.
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
bioRxiv
; 2023 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711490